Search results
Showing 1 to 7 of 7 results for belantamab mafodotin
In development Reference number: GID-TA11201 Expected publication date: 11 February 2026
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Awaiting development Reference number: GID-TA11018 Expected publication date: TBC
In development Reference number: GID-TA11203 Expected publication date: 21 January 2026
In development Reference number: GID-TA10979 Expected publication date: 11 March 2026
In development Reference number: GID-TA10568 Expected publication date: TBC
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.